[HTML][HTML] The WHO Global Tuberculosis 2021 Report–not so good news and turning the tide back to End TB
J Chakaya, E Petersen, R Nantanda, BN Mungai… - International Journal of …, 2022 - Elsevier
Objective To review the data presented in the 2021 WHO global TB report and discuss the
current constraints in the global response. Introduction and methods The WHO global TB …
current constraints in the global response. Introduction and methods The WHO global TB …
Risk factors of severe COVID-19: a review of host, viral and environmental factors
The clinical course and outcome of COVID-19 are highly variable, ranging from
asymptomatic infections to severe disease and death. Understanding the risk factors of …
asymptomatic infections to severe disease and death. Understanding the risk factors of …
[HTML][HTML] Drug resistant TB–latest developments in epidemiology, diagnostics and management
S Tiberi, N Utjesanovic, J Galvin, R Centis… - International Journal of …, 2022 - Elsevier
Aim The aim of this review is to inform the reader on the latest developments in
epidemiology, diagnostics and management. Epidemiology Drug-resistant Tuberculosis (DR …
epidemiology, diagnostics and management. Epidemiology Drug-resistant Tuberculosis (DR …
Antibody and B cell responses to SARS-CoV-2 infection and vaccination: the end of the beginning
As the COVID-19 pandemic has evolved during the past years, interactions between human
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …
Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19
C Kartsonaki, JK Baillie, NG Barrio… - International journal …, 2023 - academic.oup.com
Background We describe demographic features, treatments and clinical outcomes in the
International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID …
International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID …
Clinical standards for the diagnosis, treatment and prevention of TB infection
GB Migliori, SJ Wu, A Matteelli, D Zenner… - … of Tuberculosis and …, 2022 - ingentaconnect.com
BACKGROUND: Tuberculosis (TB) preventive therapy (TPT) decreases the risk of
developing TB disease and its associated morbidity and mortality. The aim of these clinical …
developing TB disease and its associated morbidity and mortality. The aim of these clinical …
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort
GT Network, N Casco, AL Jorge… - European …, 2023 - Eur Respiratory Soc
Background Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus
disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes …
disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes …
The COVID-19 and TB syndemic: the way forward
A Trajman, I Felker, LC Alves, I Coutinho… - … of Tuberculosis and …, 2022 - ingentaconnect.com
Together, SARS-CoV-2 and M. tuberculosis have killed approximately 5.7 million people
worldwide over the past 2 years. The COVID-19 pandemic, and the non-pharmaceutical …
worldwide over the past 2 years. The COVID-19 pandemic, and the non-pharmaceutical …
Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) and Coronavirus disease-
2019 (COVID-19), whose etiologic agent is severe acute respiratory syndrome coronavirus …
2019 (COVID-19), whose etiologic agent is severe acute respiratory syndrome coronavirus …
A mathematical model for the co-dynamics of COVID-19 and tuberculosis
In this study, we formulated and analyzed a deterministic mathematical model for the co-
infection of COVID-19 and tuberculosis, to study the co-dynamics and impact of each …
infection of COVID-19 and tuberculosis, to study the co-dynamics and impact of each …